Omeros Co. (NASDAQ:OMER - Get Free Report) shares dropped 4.4% during trading on Friday . The stock traded as low as $8.66 and last traded at $8.61. Approximately 99,645 shares traded hands during trading, a decline of 83% from the average daily volume of 578,914 shares. The stock had previously closed at $9.01.
OMER has been the subject of a number of research analyst reports. D. Boral Capital restated a "buy" rating and issued a $36.00 target price on shares of Omeros in a research note on Thursday, January 16th. Rodman & Renshaw started coverage on Omeros in a research note on Thursday, November 14th. They set a "buy" rating and a $9.00 price objective for the company. RODMAN&RENSHAW upgraded Omeros to a "strong-buy" rating in a research note on Thursday, November 14th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Omeros in a report on Thursday, November 14th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a report on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Omeros currently has an average rating of "Moderate Buy" and an average target price of $22.50.
Read Our Latest Stock Report on OMER
The company has a market cap of $481.10 million, a PE ratio of -3.58 and a beta of 2.01. The business has a 50-day simple moving average of $9.65 and a 200-day simple moving average of $6.13.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMER. Rhumbline Advisers raised its position in Omeros by 6.1% in the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company's stock valued at $454,000 after purchasing an additional 6,435 shares during the period. AQR Capital Management LLC acquired a new position in shares of Omeros in the second quarter worth $105,000. SG Americas Securities LLC acquired a new position in shares of Omeros in the third quarter worth $80,000. SPC Financial Inc. acquired a new position in shares of Omeros in the third quarter worth $77,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Omeros by 4.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company's stock worth $1,926,000 after acquiring an additional 18,454 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company's stock.
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.